Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 17, 2019

Primary Completion Date

September 21, 2022

Study Completion Date

November 24, 2023

Conditions

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Interventions

DRUG

Bortezomib

Given SC

DRUG

Metformin Hydrochloride

Given PO

DRUG

Nelfinavir Mesylate

Given PO

Trial Locations (2)

Mayo Clinic, Jacksonville

Mayo Clinic in Rochester, Rochester